出版：MarketsandMarkets（マーケッツアンドマーケッツ） 出版年月：2023年7月
初代細胞市場 : タイプ (造血、皮膚細胞、肝細胞、消化管、肺、腎臓、心臓、筋骨格系)、起源 (ヒト初代細胞、動物初代細胞)、エンドユーザー (製薬バイオテクノロジー、CRO、学術界)、地域別 – 2028年までの世界予測
Primary Cells Market by Type (Hematopoietic, Dermatocytes, Hepatocytes, Gastrointestinal, Lung, Renal, Heart, Musculoskeletal), Origin (Human Primary Cells, Animal Primary Cells), End User (Pharma Biotech, CROs, Academia), Region – Global Forecast to 2028
| ページ数 | 217 |
| 図表数 | 216 |
| 種別 | 英文調査報告書 |
| 価格 |
The global primary cells market is projected to reach USD 2.8 billion by 2028 from USD 1.7 billion in 2023, at a CAGR of 10.5% during the forecast period. On the basis of origin, the primary cells market is divided into animal and human primary cells. In 2022, the human primary cells segment accounted for the largest share of the primary cells market. Human primary cells are used for the development of novel cancer therapies, for studying human cancerous cell models and toxicology studies, and in the cosmetic industry. The other key driving factors for the human primary cells market include the demand for accurate disease models, the rise of regenerative medicine, safety testing requirements, and technological innovations within the scientific community.
“Hematopoietic cells segment accounted for the largest share in the primary cells market, by type in 2022.” Based on type, the primary cells market is segmented into hematopoietic cells, dermatophytes, gastrointestinal cells, hepatocytes, lung cells, renal cells, heart cells, musculoskeletal cells, and other primary cells. In 2022, the hematopoietic cells segment accounted for the largest market share. Hematopoietic cell transplants are frequently and constantly used to develop novel cancer therapies to treat blood cancers and other disorders of the immune system. Hematopoietic cells are also used to understand the biochemical pathways of tumor cells and the efficacy of different drugs. As a result, this segment accounts for the largest market share of the market.
“In 2022, the pharmaceutical & biotechnology companies, and CROs segment accounted for the largest share of the global primary cells market, by the end user.” On the basis of end users, the primary cells market is segmented into pharmaceutical & biotechnology companies, and CROs, academic & research institutes, and other end users. In 2022, pharmaceutical & biotechnology companies and CROs accounted for the largest share of the primary cells market, mainly due to the high adoption of primary cells in cell-based experiments and cancer research in pharmaceutical & biotechnology companies and CROs; and the increasing number of R&D facilities globally.
“Asia Pacific, primary cells market, is expected to witness the highest growth during the forecast period.” In 2022, North America accounted for the largest share of the primary cells market, followed by Europe. North America and Europe are the preferred locations for drug discovery due to established clusters in these regions, resulting in the largest market for primary cells. The Asia Pacific is projected to register the highest CAGR during the forecast period. Growth in this region is expected to be centered on China and Japan. Factors such as the presence of a large population and the rising incidence of cancer, increasing R&D spending on biopharmaceutical projects, and the growth of the biotechnology industry in developing countries are the major factors contributing to the growth of the Asia Pacific market are driving the growth of the primary cells market in this region. A breakdown of the primary participants referred to for this report is provided below:
By Company: Tier 1 – 20%, Tier 2 – 45%, Tier 3- 35% By Designation: C-Level–30%, Directors – 20%, and Others – 50% By Region: North America–36%, Europe–25%, Asia Pacific–27%, RoW-12% The prominent players in the global primary cells market are Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), AllCells (US), American Type Culture Collection (ATCC), and Axol Bioscience Ltd. (UK), among others.
Research Coverage: The report analyzes the primary cells market and aims to estimate the market size and future growth potential. The report also includes an in-depth competitive analysis of the key players in this market, along with their company profiles, product offerings, and recent developments. Reasons to Buy the Report
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall primary cells market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Increasing cancer research, Advantages of primary human cells over cell lines, Increasing demand for monoclonal antibodies, Rapid growth in the biotechnology and biopharmaceutical industries, Growing focus on personalized medicine, Government investments for cell-based research), restraints (Concerns regarding primary cell culture contamination, Ethical concerns regarding research in cell biology), opportunities (Advancing biomedical research using primary cells in 3D cultures), and challenges (Sourcing and availability of primary cells) influencing the growth of the primary cells market
• Product Development/Innovation: Detailed insights on upcoming trends, research & development activities, and new product launches in the Primary Cells Market
• Market Development: Comprehensive information about lucrative markets – the report analyses the primary cells market across varied regions
• Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the primary cells market
• Competitive Assessment: In-depth assessment of market shares, growth strategies and product offerings of leading players like Thermo Fisher Scientific Inc. (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), Corning Incorporated (US), Lonza (Switzerland), Cell Biologics, Inc. (US), PromoCell GmbH (Germany), ZenBio, Inc. (US), STEMCELL Technologies, Inc. (Canada), AllCells (US), American Type Culture Collection (ATCC), and Axol Bioscience Ltd. (UK).
目次
1 INTRODUCTION 26
1.1 STUDY OBJECTIVES 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 27
1.3 STUDY SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 YEARS CONSIDERED 28
1.4 CURRENCY 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 29
1.7 SUMMARY OF CHANGES 29
1.8 RECESSION IMPACT 30
2 RESEARCH METHODOLOGY 31
2.1 RESEARCH DATA 31
FIGURE 1 PRIMARY CELLS MARKET: RESEARCH DESIGN 31
2.1.1 SECONDARY RESEARCH 32
2.1.2 PRIMARY RESEARCH 33
FIGURE 2 PRIMARY CELLS MARKET: BREAKDOWN OF PRIMARIES 33
2.2 MARKET SIZE ESTIMATION 34
FIGURE 3 PRIMARY CELLS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2022 34
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 – REVENUE SHARE ANALYSIS (2022) 35
FIGURE 5 ILLUSTRATIVE EXAMPLE OF MERCK KGAA: REVENUE SHARE ANALYSIS (2022) 35
FIGURE 6 KEY INDUSTRY INSIGHTS 36
2.3 GROWTH FORECAST 37
FIGURE 7 PRIMARY CELLS MARKET: CAGR PROJECTIONS, 2023–2028 37
FIGURE 8 PRIMARY CELLS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 38
2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 39
FIGURE 9 DATA TRIANGULATION METHODOLOGY 39
2.5 RESEARCH ASSUMPTIONS 40
2.6 RISK ANALYSIS 40
2.7 RECESSION IMPACT 40
TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH) 40
TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 41
TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 41
3 EXECUTIVE SUMMARY 42
FIGURE 10 PRIMARY CELLS MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION) 42
FIGURE 11 PRIMARY CELLS MARKET, BY ORIGIN, 2023 VS. 2028 (USD MILLION) 43
FIGURE 12 PRIMARY CELLS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 43
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF PRIMARY CELLS MARKET 44
4 PREMIUM INSIGHTS 45
4.1 PRIMARY CELLS MARKET OVERVIEW 45
FIGURE 14 GROWING GLOBAL INCIDENCE OF CANCER TO DRIVE MARKET GROWTH 45
4.2 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER AND COUNTRY (2022) 46
FIGURE 15 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS DOMINATED NORTH AMERICAN PRIMARY CELLS MARKET IN 2022 46
4.3 PRIMARY CELLS MARKET SHARE, BY TYPE, 2023 VS. 2028 46
FIGURE 16 HEMATOPOIETIC CELLS SEGMENT TO DOMINATE MARKET IN 2028 46
4.4 PRIMARY CELLS MARKET SHARE, BY ORIGIN, 2022 47
FIGURE 17 HUMAN PRIMARY CELLS SEGMENT DOMINATED MARKET IN 2022 47
4.5 PRIMARY CELLS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 47
FIGURE 18 ASIA PACIFIC COUNTRIES TO REGISTER HIGH GROWTH RATES FROM 2023 TO 2028 47
5 MARKET OVERVIEW 48
5.1 INTRODUCTION 48
5.2 MARKET DYNAMICS 48
FIGURE 19 PRIMARY CELLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 48
TABLE 4 PRIMARY CELLS MARKET: IMPACT ANALYSIS 49
5.2.1 DRIVERS 49
5.2.1.1 Increasing cancer research 49
TABLE 5 PROJECTED INCREASE IN NUMBER OF CANCER PATIENTS, 2015 VS. 2018 VS. 2020 VS. 2035 50
TABLE 6 ESTIMATED NUMBER OF NEW CASES OF ALL CANCERS (EXCLUDING NON-MELANOMA SKIN CANCER) FOR BOTH SEXES, 2020 VS. 2040 50
5.2.1.2 Advantages of primary human cells over cell lines 51
5.2.1.3 Increasing demand for monoclonal antibodies 52
5.2.1.4 Rapid growth in biotechnology and biopharmaceutical industries 52
FIGURE 20 GLOBAL PHARMACEUTICAL R&D SPENDING, 2014–2028 53
5.2.1.5 Growing focus on personalized medicine 53
TABLE 7 GROWTH IN NUMBER OF PERSONALIZED MEDICATIONS, 2015–2022 54
5.2.1.6 Government investments for cell-based research 54
5.2.2 RESTRAINTS 55
5.2.2.1 Concerns regarding primary cell culture contamination 55
5.2.2.2 Ethical concerns regarding research in cell biology 55
5.2.3 OPPORTUNITIES 56
5.2.3.1 Advancing biomedical research using primary cells in 3D cultures 56
5.2.4 CHALLENGES 56
5.2.4.1 Sourcing and availability of primary cells 56
5.3 REGULATORY ANALYSIS 57
5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 57
5.4 PRICING ANALYSIS 58
TABLE 8 AVERAGE PRICE OF PRIMARY CELL PRODUCTS, BY KEY PLAYER (USD) 58
5.5 VALUE CHAIN ANALYSIS 59
FIGURE 21 MAJOR VALUE ADDED DURING MANUFACTURING & ASSEMBLY PHASE 60
5.6 SUPPLY CHAIN ANALYSIS 60
FIGURE 22 DISTRIBUTION—A STRATEGY PREFERRED BY PROMINENT COMPANIES 61
5.7 ECOSYSTEM ANALYSIS 62
FIGURE 23 ECOSYSTEM ANALYSIS OF PRIMARY CELLS MARKET 62
TABLE 9 PRIMARY CELLS MARKET ECOSYSTEM 63
5.8 KEY CONFERENCES & EVENTS, 2023–2024 64
TABLE 10 PRIMARY CELLS MARKET: LIST OF CONFERENCES & EVENTS 64
5.9 TECHNOLOGY ANALYSIS 64
5.10 PORTER’S FIVE FORCES ANALYSIS 65
TABLE 11 PRIMARY CELLS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
5.10.1 THREAT OF NEW ENTRANTS 65
5.10.2 THREAT OF SUBSTITUTES 65
5.10.3 BARGAINING POWER OF SUPPLIERS 65
5.10.4 BARGAINING POWER OF BUYERS 66
5.10.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.11 KEY STAKEHOLDERS & BUYING CRITERIA 66
5.11.1 KEY STAKEHOLDERS IN BUYING PROCESS 66
FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF PRIMARY CELL PRODUCTS 66
5.11.2 BUYING CRITERIA FOR PRIMARY CELLS 67
FIGURE 25 KEY BUYING CRITERIA FOR END USERS 67
6 PRIMARY CELLS MARKET, BY TYPE 68
6.1 INTRODUCTION 69
TABLE 12 PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 69
6.2 HEMATOPOIETIC CELLS 70
6.2.1 INCREASING CANCER RESEARCH & FUNDING TO PROPEL MARKET GROWTH 70
TABLE 13 TYPES OF HEMATOPOIETIC CELLS 70
TABLE 14 HEMATOPOIETIC CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 70
TABLE 15 NORTH AMERICA: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
TABLE 16 EUROPE: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
TABLE 17 ASIA PACIFIC: HEMATOPOIETIC CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 71
6.3 DERMATOCYTES 72
6.3.1 RISING PREVALENCE OF MELANOMA TO BOOST DEMAND 72
TABLE 18 DERMATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION) 72
TABLE 19 NORTH AMERICA: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 20 EUROPE: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
TABLE 21 ASIA PACIFIC: DERMATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 73
6.4 GASTROINTESTINAL CELLS 74
6.4.1 GROWING INCIDENCE OF STOMACH CANCER TO BOLSTER GROWTH 74
TABLE 22 GASTROINTESTINAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 74
TABLE 23 NORTH AMERICA: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 74
TABLE 24 EUROPE: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
TABLE 25 ASIA PACIFIC: GASTROINTESTINAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 75
6.5 HEPATOCYTES 75
TABLE 26 GLOBAL LIVER DISORDER INCIDENCE 76
TABLE 27 HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION) 77
TABLE 28 NORTH AMERICA: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 29 EUROPE: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 77
TABLE 30 ASIA PACIFIC: HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 78
TABLE 31 HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 78
6.5.1 CRYOPRESERVED HEPATOCYTES 78
6.5.1.1 Longer lifespan of cryopreserved hepatocytes than fresh hepatocytes to drive market growth 78
TABLE 32 CRYOPRESERVED HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION) 79
TABLE 33 NORTH AMERICA: CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 34 EUROPE: CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 79
TABLE 35 ASIA PACIFIC CRYOPRESERVED HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 80
6.5.2 FRESH HEPATOCYTES 80
6.5.2.1 Stringent regulations and limited availability of fresh hepatocytes to limit market growth 80
TABLE 36 FRESH HEPATOCYTES MARKET, BY REGION, 2021–2028 (USD MILLION) 80
TABLE 37 NORTH AMERICA: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 38 EUROPE: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
TABLE 39 ASIA PACIFIC: FRESH HEPATOCYTES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 81
6.6 LUNG CELLS 82
6.6.1 INCREASING RATE OF LUNG CANCER & COPD TO DRIVE DEMAND FOR LUNG CELLS 82
TABLE 40 LUNG CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 82
TABLE 41 NORTH AMERICA: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 42 EUROPE: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
TABLE 43 ASIA PACIFIC: LUNG CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 83
6.7 RENAL CELLS 84
6.7.1 LACK OF AVAILABILITY OF EFFECTIVE RENAL THERAPIES TO PROPEL MARKET GROWTH 84
TABLE 44 RENAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 84
TABLE 45 NORTH AMERICA: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84
TABLE 46 EUROPE: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
TABLE 47 ASIA PACIFIC: RENAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85
6.8 HEART CELLS 85
6.8.1 HIGH INCIDENCE OF CARDIOVASCULAR DISEASES TO SUPPORT GROWTH 85
TABLE 48 HEART CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 86
TABLE 49 NORTH AMERICA: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 50 EUROPE: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 86
TABLE 51 ASIA PACIFIC: HEART CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87
6.9 MUSCULOSKELETAL CELLS 87
6.9.1 RISING INCIDENCE OF MUSCULOSKELETAL DISORDERS TO PROPEL MARKET GROWTH 87
TABLE 52 MUSCULOSKELETAL CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 88
TABLE 53 NORTH AMERICA: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 54 EUROPE: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88
TABLE 55 ASIA PACIFIC: MUSCULOSKELETAL CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 89
6.10 OTHER PRIMARY CELLS 89
TABLE 56 OTHER PRIMARY CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 89
TABLE 57 NORTH AMERICA: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 58 EUROPE: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
TABLE 59 ASIA PACIFIC: OTHER PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90
7 PRIMARY CELLS MARKET, BY ORIGIN 91
7.1 INTRODUCTION 92
TABLE 60 PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 92
7.2 HUMAN PRIMARY CELLS 92
7.2.1 INCREASING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH 92
TABLE 61 HUMAN PRIMARY CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 93
TABLE 62 NORTH AMERICA: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93
TABLE 63 EUROPE: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
TABLE 64 ASIA PACIFIC: HUMAN PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94
7.3 ANIMAL PRIMARY CELLS 94
7.3.1 RISING INVESTMENTS IN ANIMAL CELL RESEARCH TO PROPEL MARKET GROWTH 94
TABLE 65 ANIMAL PRIMARY CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 95
TABLE 66 NORTH AMERICA: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 95
TABLE 67 EUROPE: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
TABLE 68 ASIA PACIFIC: ANIMAL PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 96
8 PRIMARY CELLS MARKET, BY END USER 97
8.1 INTRODUCTION 98
TABLE 69 PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 98
8.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS 98
8.2.1 INCREASING INVESTMENTS IN CELL-BASED RESEARCH TO DRIVE MARKET GROWTH 98
TABLE 70 PRIMARY CELLS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY REGION, 2021–2028 (USD MILLION) 99
TABLE 71 NORTH AMERICA: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 72 EUROPE: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION) 99
TABLE 73 ASIA PACIFIC: PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES AND CROS, BY COUNTRY, 2021–2028 (USD MILLION) 100
8.3 ACADEMIC & RESEARCH INSTITUTES 100
8.3.1 INCREASING GOVERNMENT FUNDING FOR RESEARCH AND HIGH PREVALENCE OF CANCER TO FAVOR MARKET GROWTH 100
TABLE 74 PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 101
TABLE 75 NORTH AMERICA: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 76 EUROPE: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 101
TABLE 77 ASIA PACIFIC: PRIMARY CELLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 102
8.4 OTHER END USERS 102
TABLE 78 PRIMARY CELLS MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION) 102
TABLE 79 NORTH AMERICA: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 80 EUROPE: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 103
TABLE 81 ASIA PACIFIC: PRIMARY CELLS MARKET FOR OTHER END USERS, BY COUNTRY, 2021–2028 (USD MILLION) 103
9 PRIMARY CELLS MARKET, BY REGION 104
9.1 INTRODUCTION 105
TABLE 82 PRIMARY CELLS MARKET, BY REGION, 2021–2028 (USD MILLION) 105
9.2 NORTH AMERICA 105
FIGURE 26 NORTH AMERICA: PRIMARY CELLS MARKET SNAPSHOT 106
TABLE 83 NORTH AMERICA: PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 106
TABLE 84 NORTH AMERICA: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 107
TABLE 85 NORTH AMERICA: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 107
TABLE 86 NORTH AMERICA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 108
TABLE 87 NORTH AMERICA: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 108
9.2.1 US 108
9.2.1.1 High R&D spending and growing support for stem cell research to drive market growth 108
TABLE 88 US: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 109
TABLE 89 US: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 90 US: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 110
TABLE 91 US: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 111
9.2.2 CANADA 111
9.2.2.1 Presence of advanced R&D infrastructure to boost market 111
TABLE 92 CANADA: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 112
TABLE 93 CANADA: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 112
TABLE 94 CANADA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 113
TABLE 95 CANADA: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 113
9.2.3 NORTH AMERICA: IMPACT OF RECESSION 113
9.3 EUROPE 114
TABLE 96 EUROPE: PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 114
TABLE 97 EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 114
TABLE 98 EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 99 EUROPE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 115
TABLE 100 EUROPE: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 116
9.3.1 UK 116
9.3.1.1 Growth in life science industry to fuel market growth 116
TABLE 101 UK: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 117
TABLE 102 UK: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 117
TABLE 103 UK: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 118
TABLE 104 UK: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 118
9.3.2 GERMANY 118
9.3.2.1 Increasing life science research activities to support market growth 118
TABLE 105 GERMANY: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 119
TABLE 106 GERMANY: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 119
TABLE 107 GERMANY: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 120
TABLE 108 GERMANY: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 120
9.3.3 FRANCE 120
9.3.3.1 Robust biotechnology infrastructure to support growth 120
TABLE 109 FRANCE: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 121
TABLE 110 FRANCE: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 111 FRANCE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 122
TABLE 112 FRANCE: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 123
9.3.4 ITALY 123
9.3.4.1 Increasing number of cell biology seminars and conferences to fuel adoption of primary cells 123
TABLE 113 ITALY: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 124
TABLE 114 ITALY: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 124
TABLE 115 ITALY: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 125
TABLE 116 ITALY: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 125
9.3.5 REST OF EUROPE 125
TABLE 117 REST OF EUROPE: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 126
TABLE 118 REST OF EUROPE: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 126
TABLE 119 REST OF EUROPE: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 127
TABLE 120 REST OF EUROPE: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 127
9.3.6 EUROPE: IMPACT OF RECESSION 128
9.4 ASIA PACIFIC 128
FIGURE 27 ASIA PACIFIC: PRIMARY CELLS MARKET SNAPSHOT 129
TABLE 121 ASIA PACIFIC: PRIMARY CELLS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 129
TABLE 122 ASIA PACIFIC: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 130
TABLE 123 ASIA PACIFIC: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 130
TABLE 124 ASIA PACIFIC: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 131
TABLE 125 ASIA PACIFIC: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 131
9.4.1 CHINA 131
9.4.1.1 Growing focus on cancer therapeutics-related research to bolster growth 131
TABLE 126 CHINA: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 132
TABLE 127 CHINA: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 132
TABLE 128 CHINA: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 133
TABLE 129 CHINA: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 133
9.4.2 JAPAN 133
9.4.2.1 Government initiatives to propel market growth in Japan 133
TABLE 130 JAPAN: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 134
TABLE 131 JAPAN: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 134
TABLE 132 JAPAN: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 135
TABLE 133 JAPAN: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 135
9.4.3 REST OF ASIA PACIFIC 135
TABLE 134 REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 136
TABLE 135 REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 136
TABLE 136 REST OF ASIA PACIFIC: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 137
TABLE 137 REST OF ASIA PACIFIC: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 137
9.4.4 ASIA PACIFIC: IMPACT OF RECESSION 137
9.5 REST OF THE WORLD 138
TABLE 138 REST OF THE WORLD: PRIMARY CELLS MARKET, BY ORIGIN, 2021–2028 (USD MILLION) 139
TABLE 139 REST OF THE WORLD: PRIMARY CELLS MARKET, BY TYPE, 2021–2028 (USD MILLION) 139
TABLE 140 REST OF THE WORLD: HEPATOCYTES MARKET, BY TYPE, 2021–2028 (USD MILLION) 140
TABLE 141 REST OF THE WORLD: PRIMARY CELLS MARKET, BY END USER, 2021–2028 (USD MILLION) 140
9.5.1 REST OF THE WORLD: IMPACT OF RECESSION 141
10 COMPETITIVE LANDSCAPE 142
10.1 INTRODUCTION 142
10.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS 142
FIGURE 28 PRIMARY CELLS MARKET: STRATEGIES ADOPTED 142
10.3 REVENUE SHARE ANALYSIS 143
FIGURE 29 REVENUE ANALYSIS OF KEY PLAYERS (2019–2022) 143
10.4 MARKET SHARE ANALYSIS 143
FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022) 144
TABLE 142 PRIMARY CELLS MARKET: DEGREE OF COMPETITION 144
10.5 COMPANY EVALUATION QUADRANT 145
FIGURE 31 PRIMARY CELLS MARKET: COMPANY EVALUATION MATRIX, 2022 146
10.5.1 STARS 146
10.5.2 EMERGING LEADERS 146
10.5.3 PERVASIVE PLAYERS 147
10.5.4 PARTICIPANTS 147
10.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 147
10.6.1 PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES) 147
TABLE 143 PRIMARY CELLS MARKET: PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS 147
10.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 148
TABLE 144 PRIMARY CELLS MARKET: REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS 148
10.7 COMPANY EVALUATION QUADRANT: START-UPS/SMES 149
FIGURE 32 PRIMARY CELLS MARKET: COMPANY EVALUATION MATRIX FOR START-UPS/SMES, 2022 149
10.7.1 PROGRESSIVE COMPANIES 150
10.7.2 STARTING BLOCKS 150
10.7.3 RESPONSIVE COMPANIES 150
10.7.4 DYNAMIC COMPANIES 150
10.8 COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 150
TABLE 145 PRIMARY CELLS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 150
TABLE 146 PRIMARY CELLS MARKET: COMPETITIVE BENCHMARKING OF START-UP/SME PLAYERS 152
10.9 COMPETITIVE SCENARIO AND TRENDS 152
10.9.1 PRODUCT LAUNCHES 152
TABLE 147 PRIMARY CELLS MARKET: PRODUCT LAUNCHES, JANUARY 2020–JUNE 2023 153
10.9.2 DEALS 153
TABLE 148 PRIMARY CELLS MARKET: DEALS, JANUARY 2020–JUNE 2023 153
10.9.3 OTHER DEVELOPMENTS 154
TABLE 149 PRIMARY CELLS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JUNE 2023 154
11 COMPANY PROFILES 155
11.1 MAJOR PLAYERS 155
(Business overview, Products offered, Recent Developments, MNM view)*
11.1.1 THERMO FISHER SCIENTIFIC, INC. 155
TABLE 150 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW 155
FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2022) 156
11.1.2 MERCK KGAA 159
TABLE 151 MERCK KGAA: COMPANY OVERVIEW 159
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2022) 160
TABLE 152 OTHER DEVELOPMENTS 161
11.1.3 CORNING INCORPORATED 163
TABLE 153 CORNING INCORPORATED: BUSINESS OVERVIEW 163
FIGURE 35 CORNING INCORPORATED: COMPANY SNAPSHOT (2022) 164
11.1.4 LONZA GROUP 166
TABLE 154 LONZA GROUP: BUSINESS OVERVIEW 166
FIGURE 36 LONZA GROUP: COMPANY SNAPSHOT (2022) 167
TABLE 155 PRODUCT LAUNCHES 169
11.1.5 CHARLES RIVER LABORATORIES, INC. 170
TABLE 156 CHARLES RIVER LABORATORIES, INC.: BUSINESS OVERVIEW 170
FIGURE 37 CHARLES RIVER LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 171
TABLE 157 ACQUISITIONS 172
11.1.6 PROMOCELL GMBH 173
TABLE 158 PROMOCELL GMBH: BUSINESS OVERVIEW 173
TABLE 159 PRODUCT LAUNCHES 174
11.1.7 AMERICAN TYPE CULTURE COLLECTION (ATCC) 175
TABLE 160 AMERICAN TYPE CULTURE COLLECTION (ATCC): BUSINESS OVERVIEW 175
11.1.8 CELL BIOLOGICS, INC. 180
TABLE 161 CELL BIOLOGICS, INC.: BUSINESS OVERVIEW 180
11.1.9 ZENBIO, INC. 185
TABLE 162 ZENBIO, INC.: BUSINESS OVERVIEW 185
11.1.10 STEMCELL TECHNOLOGIES, INC. 187
TABLE 163 STEMCELL TECHNOLOGIES, INC.: BUSINESS OVERVIEW 187
11.1.11 ALLCELLS 193
TABLE 164 ALLCELLS: BUSINESS OVERVIEW 193
11.1.12 IXCELLS BIOTECHNOLOGIES 194
TABLE 165 IXCELLS BIOTECHNOLOGIES: BUSINESS OVERVIEW 194
TABLE 166 AGREEMENTS 200
11.1.13 NEUROMICS 201
TABLE 167 NEUROMICS: BUSINESS OVERVIEW 201
*Details on Business overview, Products offered, Recent Developments, MNM view might not be captured in case of unlisted companies.
11.2 OTHER COMPANIES 202
11.2.1 AXOL BIOSCIENCE LTD. 202
TABLE 168 AXOL BIOSCIENCE LTD.: COMPANY OVERVIEW 202
11.2.2 STEMEXPRESS 203
TABLE 169 STEMEXPRESS: COMPANY OVERVIEW 203
11.2.3 BIOIVT 204
TABLE 170 BIOIVT: COMPANY OVERVIEW 204
11.2.4 SCIENCELL RESEARCH LABORATORIES, INC. 205
TABLE 171 SCIENCELL RESEARCH LABORATORIES, INC.: COMPANY OVERVIEW 205
11.2.5 AMSBIO 207
TABLE 172 AMSBIO: COMPANY OVERVIEW 207
11.2.6 PROMAB BIOTECHNOLOGIES, INC. 208
TABLE 173 PROMAB BIOTECHNOLOGIES, INC.: COMPANY OVERVIEW 208
11.2.7 CREATIVE BIOARRAY 209
TABLE 174 CREATIVE BIOARRAY: COMPANY OVERVIEW 209
11.2.8 BPS BIOSCIENCE, INC. 211
TABLE 175 BPS BIOSCIENCE, INC.: COMPANY OVERVIEW 211
11.2.9 EPITHELIX 212
TABLE 176 EPITHELIX: COMPANY OVERVIEW 212
11.2.10 REACHBIO RESEARCH LABS 213
TABLE 177 REACHBIO RESEARCH LABS: COMPANY OVERVIEW 213
11.2.11 ACCEGEN 214
TABLE 178 ACCEGEN: COMPANY OVERVIEW 214
11.2.12 KOSHEEKA 215
TABLE 179 KOSHEEKA: COMPANY OVERVIEW 215
12 APPENDIX 216
12.1 DISCUSSION GUIDE 216
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 219
12.3 CUSTOMIZATION OPTIONS 221
12.4 RELATED REPORTS 221
12.5 AUTHOR DETAILS 222